secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001159036-25-000033
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q2 revenue $326M (+41% YoY); raises FY25 guidance, files patent suit vs Merck
--------------------------------------------------------------------------------

- Q2 total revenue $325.7M (+41% YoY); royalty revenue $205.6M (+65% YoY).
- GAAP diluted EPS $1.33 (+85% YoY); Non-GAAP diluted EPS $1.54 (+69% YoY).
- Raises 2025 total revenue guidance to $1.275-1.355B (26-33% YoY) and Non-GAAP EPS to $6.00-6.40.
- Completed $303M share repurchases in Q2; initiated third $250M tranche under $750M program.
- Filed patent infringement lawsuit against Merck alleging unauthorized use of MDASE technology for SC Keytruda.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000033/0001159036-25-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000033/halo-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001159036-25-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer